Testing effectiveness (Phase 2)Looking for participantsNCT06303193
What this trial is testing
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Who this might be right for
Myelodysplastic Syndromes
National Cancer Institute (NCI) 160